|
| 37541280 | National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: challenges and recommended priorities. | Lancet Oncol | 2023 |
| 36074155 | Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases. | Clin Cancer Res | 2023 |
| 36403183 | Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2â¿¿+â¿¿breast cancer. | Breast Cancer Research and Treatment | 2023 |
| 37586926 | Triple Negative Breast Cancer and Brain Metastases. | | 2023 |
| 36585450 | Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. | Nat Cancer | 2023 |
| 37204246 | Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors. | J Immunol | 2023 |
| 36705597 | Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases. | Clin Cancer Res | 2023 |
| 36883201 | Progress for patients with melanoma brain metastases. | | 2023 |
| 37071254 | Available Systemic Treatments and Emerging Therapies for Breast Cancer Brain Metastases. | | 2023 |
| 36623515 | Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. | Lancet Oncol | 2023 |
| 36997605 | Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan. | NPJ Breast Cancer | 2023 |
| 36990614 | Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference. | Lancet Oncol | 2023 |
| 36920243 | The Enduring Effects of COVID for Cancer Care: Learning from Real-Life Clinical Practice. | | 2023 |
| 36454580 | Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial. | JAMA Oncol | 2023 |
| 35114123 | Nivolumab plus ipilimumab in melanoma brain metastases - Authors' reply. | Lancet Oncol | 2022 |
| 35579591 | Systemic management of brain metastases in HER2+ breast cancer in 2022. | Clinical Advances in Hematology and Oncology | 2022 |
| 35640077 | Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update. | J Clin Oncol | 2022 |
| 35640075 | Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update. | J Clin Oncol | 2022 |
| 35947812 | Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update Q and A. | JCO Oncology Practice | 2022 |
| 36338769 | Editorial: It takes a village: The expanding multi-disciplinary approach to brain metastasis. | Front Oncol | 2022 |
| 36210734 | Screening brain MRI in inflammatory breast cancer: Is it time? | Cancer | 2022 |
| 35552364 | Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. | JAMA Oncol | 2022 |
| 36136177 | Systemic Therapy Approaches for Breast Cancer Brain and Leptomeningeal Metastases. | Current Treatment Options in Oncology | 2022 |
| 35992833 | Comprehensive Analysis of the Immunogenomics of Triple-Negative Breast Cancer Brain Metastases From LCCC1419. | Front Oncol | 2022 |
| 35669439 | Systemic Therapy Type and Timing Effects on Radiation Necrosis Risk in HER2+ Breast Cancer Brain Metastases Patients Treated With Stereotactic Radiosurgery. | Front Oncol | 2022 |
| 32881421 | HER2-positive breast cancer brain metastasis: A new and exciting landscape. | Cancer Reports | 2022 |
| 35145903 | A Need for More Molecular Profiling in Brain Metastases. | Front Oncol | 2022 |
| 34934856 | Outcomes in Patients With 4 to 10 Brain Metastases Treated With Dose-Adapted Single-Isocenter Multitarget Stereotactic Radiosurgery: A Prospective Study. | Adv Radiat Oncol | 2021 |
| 33912803 | A case report of microsatellite instability (MSI)-high, amplified pancreatic adenocarcinoma with central nervous system metastasis. | | 2021 |
| 33743085 | Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer. | Current Treatment Options in Oncology | 2021 |
| 34277022 | Inpatient palliative care utilization for patients with brain metastases. | Neuro-Oncology Practice | 2021 |
| 34108203 | Development of next-generation tumor-homing induced neural stem cells to enhance treatment of metastatic cancers. | Science advances | 2021 |
| 33981951 | Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). | JNCI Cancer Spectr | 2021 |
| 33649192 | Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-positive Breast Cancer. | Clin Cancer Res | 2021 |
| 33201358 | Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase. | Breast Cancer Research and Treatment | 2021 |
| 33402399 | Salting the Soil: Targeting the Microenvironment of Brain Metastases. | Molecular Cancer Therapeutics | 2021 |
| 34859234 | Advances in the management of breast cancer brain metastases. | Neuro-Oncology Advances | 2021 |
| 34433662 | Cytotoxic Engineered Induced Neural Stem Cells as an Intravenous Therapy for Primary Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer. | Mol Cancer Ther | 2021 |
| 33409457 | Effects of Breast Cancer Adjuvant Chemotherapy Regimens on Expression of the Aging Biomarker, . | JNCI Cancer Spectrum | 2020 |
| 31971613 | Current multidisciplinary management of brain metastases. | Cancer | 2020 |
| 31969331 | ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. | Clin Cancer Res | 2020 |
| 32421449 | What's the Price? Toxicities of Targeted Therapies in Breast Cancer Care. | American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting | 2020 |
| 31780379 | Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR/HER2 Breast Cancer. | Clinical Breast Cancer | 2020 |
| 31825569 | Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. | N Engl J Med | 2020 |
| 31558424 | Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. | Clin Breast Cancer | 2020 |
| 32479604 | Receptor discordance in breast cancer brain metastases: when knowledge is power. | Neuro-Oncology | 2020 |
| 32468955 | Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. | J Clin Oncol | 2020 |
| 32641416 | Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines. | Cancer Res | 2020 |
| 32805517 | Clinicopathologic features of breast cancer reclassified as HER2-amplified by fluorescence in situ hybridization with alternative chromosome 17 probes. | Annals of Diagnostic Pathology | 2020 |
| 32694159 | A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer. | Clin Cancer Res | 2020 |